Press releases
- Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
- Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
- Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
- Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
- Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
- Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation
- Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19
- Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
- Vertex Reports Third-Quarter 2020 Financial Results
More ▼
Key statistics
On Monday, Vertex Pharmaceuticals Inc (VX1:STU) closed at 186.00, 8.14% above its 52-week low of 172.00, set on Oct 30, 2020.
52-week range
Markit short selling activity
Open | 186.16 |
---|---|
High | 187.90 |
Low | 186.00 |
Bid | 185.86 |
Offer | 187.62 |
Previous close | 187.16 |
Average volume | 238.36 |
---|---|
Shares outstanding | 260.04m |
Free float | 259.67m |
P/E (TTM) | 22.45 |
Market cap | 59.65bn USD |
EPS (TTM) | 10.22 USD |
Data delayed at least 15 minutes, as of Jan 18 2021.
More ▼